Healthy Volunteers Clinical Trial
Official title:
Randomized, Double-Blind, Double-Dummy, Placebo- and Positive Controlled, 4-Way Crossover Study to Assess the Effect of Single-Dose ACP-196 on the QTc Interval in Healthy Adult Subjects
Verified date | April 2021 |
Source | Acerta Pharma BV |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is to evaluate the effects of single therapeutic and supratherapeutic oral doses of ACP-196 on the heart rate-corrected QT interval using Fridericia's formula (QTcF).
Status | Completed |
Enrollment | 48 |
Est. completion date | May 9, 2016 |
Est. primary completion date | May 9, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Continuous non-smoker participant who has not used nicotine-containing products for >= 3 months before the first dose - Have body mass index of >= 18.0 and <= 32.0 kg/m^2 at screening - Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or electrocardiograms (ECGs), as deemed by the principal investigator (PI) - No clinically significant history or presence of ECG findings as judged by the PI or qualified designee at screening and each check-in, including each criterion as: 1) Normal sinus rhythm (heart rate between 50 and 100 beats per minute [bpm]), 2) QTcF interval = 450 milliseconds (msec), 3) QRS interval = 110 msec, and 4) PR interval = 220 msec - Women participants must be of non-childbearing status - Women participants must have negative serum pregnancy test - ability to swallow multiple capsules and/or tablets using size 0 blank capsules (up to a maximum of 5 capsules per participant) - Male participants must be willing to use protocol specified contraception methods Exclusion Criteria: - Participant is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study - History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study - Presence of any clinically significant, ongoing systemic bacterial, fungal, or viral infections (including upper respiratory tract infections, but excluding localized cutaneous fungal infections), in the opinion of the PI - History of any major surgical procedure within 30 days before the first dose of study drug - History or presence of alcoholism or drug abuse within the past 2 years before screening - Any clinically significant condition that may affect ACP-196 absorption in the opinion of the PI, including gastric restrictions and bariatric surgery (eg, gastric bypass). - Allergy to band-aids, adhesive dressing, or medical tape - History or presence of clinically significant thyroid disease - Prior exposure to Bruton's tyrosine kinase inhibitors (eg, ACP-196, ibrutinib) within 3 months before the first dose of study drug - Positive urine cotinine at screening - Positive urine drug or alcohol results at screening or each check-in - Positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at screening - Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening - Seated heart rate is lower than 50 bpm or higher than 99 bpm at screening - Unable to refrain from or anticipates the use of protocol defined medications for 28 days before the first dose of study drug and throughout the study |
Country | Name | City | State |
---|---|---|---|
United States | Celerion | Tempe | Arizona |
Lead Sponsor | Collaborator |
---|---|
Acerta Pharma BV |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The QTcF Change From Baseline at Postdose Timepoints (dQTcF) | 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Change in Time-matched QTcF Interval Following Moxifloxicin Administration Compared With Matching Placebo | 1, 2, 3, and 4 hour post moxifloxicin dose in each period | ||
Secondary | Change From Baseline in Heart Rate at Postdose Time Points | 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Change From Baseline in PR Interval at Postdose Time Points | 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Change From Baseline in RR Interval at Postdose Time Points | 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Change From Baseline in QRS Interval at Postdose Time Points | 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Change From Baseline in QT Interval at Postdose Time Points | 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Number of Participants With Nonspecific T Waves Abnormality at Postdose Time Points | 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Number of Participants With Nonspecific U Waves Abnormality at Postdose Time Points | 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of ACP-196 | -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of ACP-196 | -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Percent of AUC0-inf Extrapolated (AUC%extrap) of ACP-196 | -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Maximum Measured Plasma Concentration (Cmax) of ACP-196 | -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Time of the Maximum Measured Plasma Concentration (Tmax) of ACP-196 | -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Apparent Terminal Elimination Rate Constant (?z) of ACP-196 | -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Apparent Terminal Elimination Half-life ( t½) of ACP-196 | -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Apparent Total Plasma Clearance (CL/F) of ACP-196 | -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose in each period | ||
Secondary | Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious AEs (TESAEs) | From Day 1 through 14 days after the last dose of study drug of the last period (approximately 1 month and 8 days) | ||
Secondary | Incidence of Abnormal Clinical Laboratory Parameters Reported as TEAEs | From Day 1 through 24 hours after the last dose of study drug of the last period (approximately 1 month and 8 days) | ||
Secondary | Incidence of Abnormal Vital Signs and Physical Examinations Reported as TEAEs | From Day 1 through 24 hours after the last dose of study drug of the last period (approximately 1 month and 8 days) | ||
Secondary | Incidence of Abnormal ECGs Reported as TEAEs | From Day 1 through 24 hours after the last dose of study drug of the last period (approximately 1 month and 8 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |